Clinical trial
A 24-week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
NCT00229684 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 24-week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
- Lead sponsor
- AstraZeneca
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 30, 2004
- Completion date
- June 30, 2006
- Enrollment
- 100
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.